Mobia Medical (MOBI) Q2 2026: Revenue More Than Doubles on Commercial Expansion and IPO-Fueled Growth

August 11, 2026 | By EarningsIQ Research

Mobia Medical delivered a 102% year-over-year revenue increase driven by expanding active territories and growing adoption of its Vivistim Paired VNS therapy. The recent IPO provides substantial capital to accelerate commercialization and broaden patient access in a large, underserved stroke recovery market. Management’s confident guidance reflects durable demand and a scalable commercial model poised for continued growth.

Summary

• Commercial Expansion Accelerates: Nearly doubled active territories and increased unit sales underpin robust revenue growth.
• Capital Deployment Focused on Growth: IPO proceeds strategically allocated to scale sales infrastructure and clinical initiatives.
• Market Leadership Positioned: Vivistim therapy’s clinical validation and reimbursement progress set stage for standard of care adoption.

Business Overview

Mobia Medical is a medical device company specializing in stroke recovery solutions, primarily through its Vivistim Paired VNS therapy. This FDA-approved implantable system combines vagus nerve stimulation with physical therapy to promote neuroplasticity and improve upper limb function in chronic ischemic stroke survivors. The company generates revenue by selling implantable pulse generators and related therapy units to specialized stroke centers across the United States.

Performance Analysis

In the second quarter of 2026, Mobia Medical reported revenue of $13.5 million, a 102% increase compared to $6.7 million in the same period last year. This surge was driven by a 92% increase in average active territories to 35.5 and higher utilization within these territories, resulting in approximately 367 units sold during the quarter. Gross margin improved slightly to 83.2%, reflecting stable per unit product costs despite higher freight and tariff expenses.

Operating expenses rose 83% year-over-year to $29.2 million, primarily due to increased personnel and commission costs supporting commercial growth, as well as higher audit, legal, and marketing expenses related to the recent IPO. Research and development expenses also increased by 61%, reflecting investment in clinical development and headcount expansion. Net loss widened to $21.0 million, though net loss per share improved significantly due to a larger share base post-IPO.

• Territory Expansion and Utilization: Nearly doubling active territories and increasing unit sales per territory drove strong top-line growth.
• Margin Stability Amid Growth: Gross margin held steady above 83%, indicating efficient cost management despite scale-up.
• Investment in Commercial and Clinical Capabilities: Operating expenses rose as the company prioritized building its salesforce and evidence base.

This quarter’s results reflect Mobia’s transition from a clinical-stage company to a commercial growth story, leveraging its FDA-approved therapy and expanding footprint to capture a large, underserved market of chronic stroke survivors.

Executive Commentary

Strategic Positioning

1. Focused Commercial Model Targeting Stroke Centers

Mobia’s go-to-market strategy centers on approximately 1,500 primary and comprehensive stroke centers in the U.S., a concentrated and specialized customer base. The commercial team pairs territory managers with therapy development specialists to build infrastructure, educate providers, and establish patient referral pathways, enabling scalable and predictable growth.

2. Expanding Access Through Territory Growth and Utilization

The company nearly doubled its active territories year-over-year and continues to increase utilization within existing programs. This dual approach supports a broadening patient funnel and sustainable revenue expansion. Management’s disciplined pace in adding four to five territories per quarter balances growth with operational execution.

3. Clinical Validation and Durable Patient Outcomes

Vivistim therapy’s pivotal VNS Rehab trial demonstrated durable and clinically meaningful improvements in upper limb function extending to two years, with some patients showing continued gains at three years. This evidence base underpins physician and patient confidence and supports ongoing reimbursement discussions.

4. Reimbursement Progress Provides Stability and Predictability

Vivistim holds a category one CPT code and is included in the New Technology Ambulatory Payment Classification (APC) 1580 with an approximate Medicare reimbursement of $45,000. While coverage development with commercial payers is ongoing, the company views reimbursement as stable and predictable, forming a critical foundation for commercial scaling.

5. IPO Capital Fuels Growth Investments

The $134 million net proceeds from the IPO strengthen Mobia’s balance sheet and fund expansion of the commercial organization, including hiring and training, as well as clinical initiatives to build real-world evidence. This capital infusion enables the company to accelerate its path to becoming the standard of care in stroke recovery.

Key Considerations

Mobia Medical’s second quarter results and strategic initiatives highlight several critical factors shaping its trajectory:

• Commercial Execution Drives Growth: The company’s ability to systematically open new territories and deepen existing programs is central to scaling revenue in a specialized market.
• Clinical Evidence Supports Adoption: Durable patient outcomes and ongoing data generation are essential for provider confidence and payer coverage expansion.
• Reimbursement Environment Is Favorable but Evolving: Medicare payment codes provide a stable base, but commercial payer coverage will develop over years, requiring sustained evidence and engagement.
• Capital Deployment Is Focused and Measured: IPO proceeds are being strategically invested to build commercial capacity without overextending resources prematurely.
• Market Opportunity Is Large and Underserved: With approximately 9 million ischemic stroke survivors in the U.S. and a serviceable market estimated at over $30 billion, significant runway remains for growth.

Risks

Mobia faces execution risks related to scaling its commercial model and securing broader reimbursement coverage, particularly among commercial payers. The evolving regulatory and reimbursement landscape introduces uncertainty over timing and extent of coverage expansion. Additionally, the company’s continued net losses and reliance on capital markets for funding growth underscore financial risks that investors should monitor.

Forward Outlook

For the full year 2026, Mobia Medical guided to revenue between $54.0 million and $56.0 million, representing growth of 69% to 75% over 2025. Management emphasized confidence in the durability of its patient funnel and momentum from hospital program implementations. The company intends to continue measured territory expansion and invest in commercial and clinical capabilities to sustain growth.

Takeaways

Mobia Medical’s Q2 2026 results mark a pivotal step in its evolution from clinical validation to commercial scale-up, supported by a strong capital position and a differentiated therapy addressing a large unmet need.

• Commercial Model Scalability: The nearly doubled active territories and increasing unit sales per territory validate the effectiveness of Mobia’s focused sales approach in a specialized market.
• Evidence-Driven Adoption: Robust clinical data and durable patient outcomes are critical levers for expanding physician usage and payer coverage over time.
• Capital Enables Growth Acceleration: The IPO proceeds provide a runway to invest in growth initiatives, but disciplined execution remains essential to convert opportunity into sustained profitability.

Conclusion

Mobia Medical’s strong second quarter performance and strategic investments position it well to capitalize on a significant market opportunity in stroke recovery. The company’s scalable commercial model, supported by clinical validation and reimbursement progress, underpins confident guidance and a promising growth outlook.

Industry Read-Through

Mobia’s results underscore the growing importance of innovative neurostimulation therapies in chronic stroke recovery, a segment historically underserved by medical technology. The company’s approach to pairing device therapy with rehabilitation reflects a broader industry trend towards integrated, evidence-based solutions that extend beyond acute care. Other medtech players may look to Mobia’s commercial model and reimbursement strategy as a blueprint for addressing large, complex patient populations through specialized centers. Additionally, the emphasis on durable clinical outcomes and real-world evidence highlights the increasing role of long-term data in shaping payer and provider adoption across medical device sectors.

MOBI Healthcare Medical Devices Commercial Expansion Neurostimulation Stroke Recovery Reimbursement